Mesalamine and Serum sickness - a phase IV clinical study of FDA data

Summary:

Serum sickness is reported as a side effect among people who take Mesalamine (mesalamine), especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months also take Remicade, and have Abdominal pain.

The phase IV clinical study analyzes which people have Serum sickness when taking Mesalamine. It is created by eHealthMe based on reports of 27,767 people who have side effects when taking Mesalamine from the FDA, and is updated regularly.

What is Mesalamine?

Mesalamine has active ingredients of mesalamine. It is often used in ulcerative colitis. eHealthMe is studying from 28,053 Mesalamine users. Check the latest studies of Mesalamine.

What is Serum sickness?

Serum sickness (hypersensitivity reaction that results from the injection of heterologous or foreign protein or serum) is found to be associated with 269 drugs and 489 conditions by eHealthMe. Check the latest studies of Serum sickness.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

27,767 people reported to have side effects when taking Mesalamine.
Among them, 26 people (0.09%) have Serum sickness.

Among these 26 people:

How long have people been on Mesalamine when they have Serum sickness? *

What is the gender of people who have Serum sickness when taking Mesalamine? *

female: 73.08 %
male: 26.92 %

What is the age of people who have Serum sickness when taking Mesalamine? *

What are other drugs people take besides Mesalamine? *

What are other side effects people have besides Serum sickness? *

Rashes (redness): 14 people, 53.85%
Muscle Aches (muscle pain): 13 people, 50.00%
Muscle Spasms (muscle contraction): 12 people, 46.15%
Social Problem: 12 people, 46.15%
Skin Disorder (skin disease): 12 people, 46.15%
Cervix Carcinoma Stage 0 (abnormal cells are found in the innermost lining of the cervix. these abnormal cells may become cancer and spread into nearby normal tissue): 12 people, 46.15%
Impaired Healing: 12 people, 46.15%
Mental Disorder (a psychological term for a mental or behavioural pattern or anomaly that causes distress or disability): 12 people, 46.15%
Pancreatitis (inflammation of pancreas): 12 people, 46.15%
Drug Ineffective: 12 people, 46.15%

What are the existing conditions these people have? *

Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder): 2 people, 7.69%
Abdominal Pain: 2 people, 7.69%
Nausea (feeling of having an urge to vomit): 1 person, 3.85%
Joint Pain: 1 person, 3.85%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 1 person, 3.85%
Depression: 1 person, 3.85%
Abdominal Pain Upper: 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Mesalamine and have Serum sickness?

- Check whether Serum sickness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mesalamine:

Mesalamine (28,053 reports)

Serum sickness treatments and more:

Serum sickness (3,679 reports)

Browse all side effects of Mesalamine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Serum sickness:

Serum sickness (269 drugs)

Browse all the conditions that are associated with Serum sickness:

Serum sickness (489 conditions)

Related publications that referenced our studies

Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .
Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on mesalamine (the active ingredients of Mesalamine) and Mesalamine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.